CN117886950A - 呼吸道合胞病毒假病毒及其制备方法 - Google Patents
呼吸道合胞病毒假病毒及其制备方法 Download PDFInfo
- Publication number
- CN117886950A CN117886950A CN202311839808.4A CN202311839808A CN117886950A CN 117886950 A CN117886950 A CN 117886950A CN 202311839808 A CN202311839808 A CN 202311839808A CN 117886950 A CN117886950 A CN 117886950A
- Authority
- CN
- China
- Prior art keywords
- respiratory syncytial
- syncytial virus
- protein
- fusion
- pseudovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 73
- 241001112090 Pseudovirus Species 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims abstract description 52
- 230000004927 fusion Effects 0.000 claims abstract description 41
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 5
- 230000035772 mutation Effects 0.000 claims abstract description 4
- 239000013612 plasmid Substances 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 24
- 238000001890 transfection Methods 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 4
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 238000011278 co-treatment Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 description 28
- 238000011529 RT qPCR Methods 0.000 description 10
- 239000002033 PVDF binder Substances 0.000 description 7
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091006027 G proteins Proteins 0.000 description 5
- 102000030782 GTP binding Human genes 0.000 description 5
- 108091000058 GTP-Binding Proteins 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 241000711904 Pneumoviridae Species 0.000 description 2
- 241000711902 Pneumovirus Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 239000013639 protein trimer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了呼吸道合胞病毒假病毒及其制备方法,涉及生物技术领域。本发明提供了一种呼吸道合胞病毒融合前F蛋白,所述的呼吸道合胞病毒融合前F蛋白与野生型相比,含有以下突变中至少两种:N67I、N116Q、S215P、D486N,所述的呼吸道合胞病毒融合前F蛋白的氨基酸序列如SEQ ID NO:1所示。本发明的呼吸道合胞病毒融合前F蛋白的构象使其稳定在融合前的构象进而增加F蛋白的感染力度,并且实现了其高效表达。本发明还提供了包含上述呼吸道合胞病毒融合前F蛋白的呼吸道合胞病毒假病毒。
Description
技术领域
本发明涉及生物技术领域,具体涉及呼吸道合胞病毒假病毒及其制备方法。
背景技术
呼吸道合胞病毒(Respiratory Syncytial Virus,RSV)是一种非节段性单股负链RNA病毒,属于副黏病毒科(Paramyxoviridae)、肺炎病毒亚科(Pneumovirinae)、肺病毒属(Pneumovirus)。病毒粒子外层为脂质囊膜,内部是病毒核衣壳。病毒颗粒由包膜、核衣壳和核心组成。呼吸道合胞病毒包膜上镶嵌着三个关键的蛋白分别是SH蛋白、F蛋白和G蛋白。其中F蛋白有融合前构象(pre-fusion)和融合后构象(post-fusion)两种形式,核衣壳由壳粒组成,病毒核心是由病毒基因组RNA和N、P、L等非结构蛋白组成的复合体。
RSV是婴幼儿、免疫力低下者和老年人急性呼吸道感染的重要病原,具有易反复感染、传播快、病情进展迅速等特点。在感染早期,病毒主要在上呼吸道复制,引起鼻塞,可伴有发热、乏力和头痛等临床症状,较少部分患者会出现下呼吸道感染,引起毛细血管炎和肺炎,表现为头痛、乏力和发热等症状,重症患者易发生严重并发症,包括呼吸功能不全、肠胃功能不全、呼吸暂停及病毒性心肌炎等相关症状。
F蛋白是一种Ⅰ型跨膜糖蛋白,包含信号肽、信号肽切割位点、F2区、多肽裂解区和F1区。F蛋白三聚体包含融合前(Pre-fusion F protein,Pre-F)和融合后(Post-fusion Fprotein,Post-F)两种构象。Pre-F是一种亚稳定结构,当病毒与细胞发生融合后,Pre-F转变为稳定的Post-F。融合前构象的F蛋白感染力度更强,融合后构象的F蛋白更加稳定但是感染力度弱。以往研究主要通过呼吸道合胞病毒野毒进行抗体中和实验和利用其感染宿主进行感染机制的研究,但呼吸道合胞病毒野毒的使用本身存在安全问题且对实验室的环境要求较高。
中国专利CN116284266A中公开了突变型呼吸道合胞病毒融合前F蛋白及其应用,所述的突变型呼吸道合胞病毒融合前F蛋白,相较于野生型呼吸道合胞病毒融合前F蛋白存在以下突变:(a)F1亚基和/或F2亚基中至少一个氨基酸残基被半胱氨酸取代,(b)野生型呼吸道合胞病毒融合前F蛋白第104-144位氨基酸残基被连接肽部分或全部取代,所述连接肽的氨基酸残基长度至少两个。该发明的突变型呼吸道合胞病毒融合前F蛋白相比于同类品具有较高的中和抗体结合活性和热稳定性。但其感染力度并没有明显改善。
因此,在本领域如何改造F蛋白以实现其高效表达和提高感染力度是亟待解决的问题。
发明内容
本发明的目的是提供一种呼吸道合胞病毒融合前F蛋白,改造呼吸道合胞病毒融合前F蛋白的构象使其稳定在融合前的构象进而增加F蛋白的感染力度。
为实现上述发明目的,本发明的技术方案如下:
一方面,本发明提供了一种呼吸道合胞病毒融合前F蛋白,所述的呼吸道合胞病毒融合前F蛋白与氨基酸序列如SEQ ID NO:6相比,含有以下突变中至少两种:N67I、N116Q、S215P、D486N。
优选地,所述的呼吸道合胞病毒融合前F蛋白的氨基酸序列如SEQ ID NO:1所示。
又一方面,本发明提供了一种核酸分子,所述的核酸分子编码上述的呼吸道合胞病毒融合前F蛋白。
具体地,所述的核酸分子包含一种或多种经密码子优化的核酸分子。
又一方面,本发明提供了一种载体,所述的载体包含上述的核酸分子。
优选地,所述的载体包括但不限于质粒、病毒。
进一步地,所述的载体是病毒载体。
进一步地,所述的病毒载体为流感病毒载体、逆转录酶病毒载体或腺病毒载体。
优选地,本发明提供了一种宿主细胞,所述的宿主细胞包含上述的呼吸道合胞病毒融合前F蛋白或上述的核酸分子或上述的载体。
优选地,所述的宿主细胞选自原核细胞或真核细胞。
进一步地,所述的原核细胞选自大肠杆菌细胞。
进一步地,所述的真核细胞包括哺乳动物细胞。
再进一步地,所述的哺乳动物细胞包括小鼠细胞和人细胞。
具体地,哺乳动物细胞为人细胞,所述的人细胞包括造血细胞、上皮细胞、肝细胞、神经细胞。
又一方面,本发明提供了一种呼吸道合胞病毒假病毒,包含上述的呼吸道合胞病毒融合前F蛋白。
又一方面,本发明提供了一种呼吸道合胞病毒假病毒的制备方法,包括以下步骤:
(1)质粒pcDNA3.1+作为载体,利用限制性内切酶BamHI和EcoRI酶切获得线性化载体,通过同源重组将线性化的pcDNA3.1+载体分别与SEQ ID NO.1、SEQ ID NO:2、SEQ IDNO:3连接,分别获得pcDNA3.1-pre F质粒、pcDNA3.1-G质粒、pcDNA3.1-ZsGreen-IRES-Luc2质粒;
(2)在293T细胞中进行假病毒的包装,加入pcDNA3.1-pre F质粒、pcDNA3.1-G质粒、pcDNA3.1-ZsGreen-IRES-Luc2质粒和psPAX2质粒混匀,再加入1xPEI混匀,获得转染混合物;
(3)转染混合物加入到培养皿中,进行转染;
(4)离心,收集细胞培养基上清,加入病毒保护液进行重悬,再加入全能核酸酶,获得呼吸道合胞病毒假病毒。
优选地,步骤(2)中293T细胞密度在90%左右、无支原体且细胞状态良好才可进行细胞转染。
优选地,步骤(2)转染前每皿换液2% FBS血清的DMEM培养基。
优选地,步骤(2)中质粒的加入量为psPAX2质粒2.5ug,pcDNA3.1-ZsGreen-IRES-Luc2质粒4.5ug,pcDNA3.1-pre F质粒2ug,pcDNA3.1-G质粒2ug。
优选地,步骤(3)中转染的时间为6-8h。
优选地,步骤(4)中离心的转速为50000xg,离心的时间为2h。
又一方面,本发明提供了上述的呼吸道合胞病毒融合前F蛋白或上述的核酸分子或上述的载体或上述的宿主细胞或上述的呼吸道合胞病毒假病毒或上述的制备方法制备得到的呼吸道合胞病毒假病毒在制备治疗、预防或辅助治疗呼吸道合胞病毒感染的药物中的应用。
又一方面,本发明提供了上述的呼吸道合胞病毒融合前F蛋白或上述的核酸分子或上述的载体或上述的宿主细胞或上述的呼吸道合胞病毒假病毒或上述的制备方法制备得到的呼吸道合胞病毒假病毒在制备预防呼吸道合胞病毒感染的疫苗中的应用。
又一方面,本发明提供了一种药物组合物,包含上述的呼吸道合胞病毒融合前F蛋白或上述的核酸分子或上述的载体或上述的宿主细胞或上述的呼吸道合胞病毒假病毒或上述的制备方法制备得到的呼吸道合胞病毒假病毒。
优选地,所述的药物组合物中还包括药学上可接受的载体。
进一步地,所述的药学上可接受的载体包括但不限于赋形剂、缓冲剂、乳化剂、稳定剂、稀释剂、粘合剂、防腐剂。
具体地,所述赋形剂选自微晶纤维素、乳糖、预胶化淀粉、环糊精、羧甲基纤维素、甘露醇中的至少一种。
具体地,所述缓冲剂选自磷酸二氢钠、碳酸氢钠、碳酸氢铵、醋酸钠、枸橼酸盐、组氨酸、琥珀酸盐中的至少一种。
具体地,所述乳化剂选自硬脂酸镁、硬脂酸锌、硬脂酸钙、硬脂酸甘油酯、山梨坦异硬脂酸酯、山梨坦油酸酯、甘油油酸酯、聚甘油-3聚蓖麻醇酸酯中的至少一种。
具体地,所述稳定剂选自金合欢胶、琼脂、藻酸、纤维素醚、羧甲基甲壳酯中的至少一种。
具体地,所述稀释剂选自赤藓糖醇、甘露醇、山梨糖醇、木糖醇、乳糖、蔗糖、玉米淀粉、马铃薯淀粉、磷酸钙、柠檬酸钙、结晶纤维素中的至少一种。
具体地,所述粘合剂选自乙醇、淀粉浆、糖浆、羟丙基甲基纤维素、羧甲基纤维素钠、海藻酸钠、聚乙烯吡咯烷酮中的至少一种。
具体地,所述防腐剂选自羟苯甲酸甲酯、对羟苯甲酸丙酯、尼泊金甲酯、尼泊金乙酯、尼泊金丙酯、三氯叔丁醇、硫柳汞、氧氰化汞、苯氧乙醇、氯己定、苯甲酸、苯甲酸钠、氯甲酚、苯扎溴铵、苯扎氯铵、羟苯乙酯中的至少一种。
优选地,所述的药物的剂型选自注射剂、片剂、胶囊剂、口服液体剂型、颗粒剂、软膏剂、混悬剂、散剂、乳剂、溶液剂、滴丸剂、栓剂、气雾剂中的任意一种。
又一方面,本发明提供了一种疫苗,所述的疫苗包含上述的呼吸道合胞病毒融合前F蛋白或上述的核酸分子或上述的载体或上述的宿主细胞或上述的呼吸道合胞病毒假病毒或上述的制备方法制备得到的呼吸道合胞病毒假病毒。
优选地,所述的疫苗还可以包含佐剂。
本发明的有益效果为:
本发明提供了一种呼吸道合胞病毒融合前F蛋白,其为在野生型呼吸道合胞病毒融合前F蛋白的基础上引入了四个突变假病毒,N67I、N116Q、S215P、D486N,改造的呼吸道合胞病毒融合前F蛋白的构象使其稳定在融合前的构象进而增加F蛋白的感染力度,并且实现了其高效表达。
附图说明
图1为呼吸道合胞病毒假病毒包装、转染和检测流程模式图。
图2为pcDNA3.1-pre F质粒图谱。
图3为pcDNA3.1-G质粒图谱。
图4为pcDNA3.1-ZsGreen-IRES-Luc2质粒图谱。
图5为呼吸道合胞病毒假病毒琼脂糖凝胶成像图。
图6为呼吸道合胞病毒假病毒qPCR检测拷贝数图。
图7为呼吸道合胞病毒假病毒感染A549和Hep-2细胞系荧光图。
图8为呼吸道合胞病毒假病毒蛋白凝胶成像图。
图9为呼吸道合胞病毒假病毒双荧光素酶检测数据分析柱状图。
具体实施方式
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解,下面结合具体实施例,进一步阐明本发明,但下述实施例仅为本发明的优选实施例,并非全部。基于实施方式中的实施例,本领域技术人员在没有做出创造性劳动的前提下所获得其它实施例,都属于本发明的保护范围。下述实施例中,若无特殊说明,所用的操作方法均为常规操作方法,所用设备均为常规设备,各个实施例所用设备材料均相同。
本发明说明书中图1为呼吸道合胞病毒假病毒包装、转染和检测流程模式图。
实施例1呼吸道合胞病毒假病毒相关质粒构建
(1)全基因组合成的方法获得以下序列,具体如表1所示。
表1.
(2)质粒pcDNA3.1+作为载体,利用限制性内切酶BamHI和EcoRI酶切获得线性化载体,通过同源重组将线性化的pcDNA3.1+载体与合成的SEQ ID NO.1连接获得pcDNA3.1-preF质粒,图谱如图2所示。
(3)质粒pcDNA3.1+作为载体,利用限制性内切酶BamHI和EcoRI酶切获得线性化载体,通过同源重组将线性化的pcDNA3.1+载体与合成的SEQ ID NO.2连接获得pcDNA3.1-G质粒,图谱如图3所示。
(4)质粒pcDNA3.1+作为载体,利用限制性内切酶BamHI和EcoRI酶切获得线性化载体,通过同源重组将线性化的pcDNA3.1+载体与合成的SEQ ID NO.3接获得pcDNA3.1-ZsGreen-IRES-Luc2质粒,图谱如图4所示。
构建好的质粒取1ug跑1%的琼脂糖凝胶电泳,电压条件为120V 30min;电泳条带正确的质粒送第一代基因组测序鉴定,测序由天霖公司完成,琼脂糖凝胶电泳的结果见图5。
实施例2呼吸道合胞病毒假病毒包装实验
(1)转染前显微镜下观察293T细胞状态,密度在90%左右、无支原体且生长状态良好可进行细胞转染;
(2)转染前10cm dish细胞每皿换液10mL含2% FBS血清的DMEM培养基减少血清对质粒转染的影响;
(3)实验分组及质粒用量如下表(下表中psPAX2质粒购自addgene公司,货号为12260):
表2.
(4)按照上表的质粒和1xPEI需求量分别加入对应的含1mL 1xPBS/皿的1.5mL EP管中,先加入质粒混匀后再加入1xPEI(购自HARVEYBIO公司,货号为49553-93-7)进行混匀,静置15min获得转染混合物;
(5)转染混合物滴加到10cm dish中,转染8h小时后换液10mL含2% FBS血清的DMEM培养基;
(6)转染后48h后收集细胞培养基上清,离心机50000xg离心2h后用100ul1xPBS(购自Gibco公司,货号为70011044)进行重悬,同时按照1皿10cm dish加入25ul全能核酸酶(购自zrbiorise公司,货号为ZRXX12688)在37℃处理1h消除游离的DNA和RNA后过滤纯化获得纯化的呼吸道合胞病毒假病毒,分别命名为Pre-F+G virus、Pre-F virus和G virus。
实施例3呼吸道合胞病毒荷载量检测
(1)病毒核酸提取试剂盒(购自Beaverbio公司,货号为Cat.NO.70406)分别提取呼吸道合胞病毒假病毒RSV pre F&G、RSV pre F和RSV G携带的RNA,三种病毒携带的RNA相同(包含ZsGreen和dual Luciferase的mRNA),具体提取方法按照说明书进行。
(2)RNA利用一步法RT-qPCR试剂盒(购自诺唯赞公司,HiScript IIOne Step qRT-PCR SYBR Green Kit,货号:Q221-01)进行qPCR,该试剂盒可以同时实现RNA的逆转和qPCR。
(3)检测dual Luciferase mRNA的qPCR引物序列如下:
表3.
序列编号 | 合成序列 |
SEQ ID NO:4 | Forward Primer:CGCACATATCGAGGTGGACA |
SEQ ID NO:5 | Reverse Primer:GCAAGCTATTCTCGCTGCAC |
(4)RT-qPCR的20ul反应体系如下:
表4反应体系
按照上表反应体系在冰上配制并混匀。
(5)RT-qPCR的反应程序如下:
表5反应程序
按照上表程序设置qPCR反应程序进行qPCR反应,并导出数据进行分析,数据如图6,结果可知Pre-F virus的拷贝数相对于Pre-F+G virus和G virus较高。
实施例4呼吸道合胞病毒假病毒感染力度检测
(1)A549和Hep-2细胞系使用含10%血清的DMEM培养基进行培养,复苏细胞超过三代后观察细胞生长状态,待细胞生长至80%-90%密度且细胞状态良好时进行铺孔六孔板,共计6孔,铺孔密度30%-40%。
(2)第二天将20ul的呼吸道合胞病毒假病毒和1x助感染试剂(购自biosharp公司,货号为BL628A)混匀后加入六孔板中,六孔板按照十字摇匀法进行摇匀后置于含5% CO2的37℃细胞培养箱进行培养。
(3)感染12h左右换液2mL含10%血清的DMEM进行培养,感染72h时用荧光显微镜拍照,呼吸道合胞病毒假病毒的荧光图如图7所示,结果可知Pre-F+G virus的荧光强度相对于Pre-F virus和G virus较高。
实施例5呼吸道合胞病毒假病毒蛋白鉴定(WB)
(1)取60ul实施例2中的病毒液加上20ul的4x SDS loading buffer(购自Takara公司,货号为9173)混匀后100℃煮10min进行变性处理,变性完成后12000rpm离心2min去除杂质;
(2)上样量20ul进行聚丙烯酰胺凝胶电泳,电压条件为120V跑1h10min;
(3)电泳完成后进行转膜,使用的是PVDF膜,转膜条件为100mA转1h30min或者胶上无明显蛋白marker残留即可;
(4)转膜完成的PVDF膜使用5%的脱脂奶粉进行封闭,置于40rpm的平转摇床上孵育1h;
(5)孵育完成的PVDF用1xPBST(购自Solarbio公司,货号为P1031)清洗后分别用对应的F蛋白(购自abcam公司,货号为ab9110))和G蛋白抗体(购自abcam公司,货号为ab94966)进行4℃过夜孵育,F蛋白和G蛋白的稀释比例是1:1000;
(6)一抗孵育完成的PVDF膜使用1xPBST进行清洗,分三次进行,每次置于80rpm的平转摇床中清洗5min;
(7)清洗完成的PVDF膜加入对应抗性的二抗进行孵育,置于40rpm的平转摇床孵育1h,二抗的稀释比例是1:10000;
(8)二抗孵育完成的PVDF膜使用1xPBST进行清洗,分三次进行,每次置于80rpm的平转摇床中清洗5min;
(9)洗膜完成的PVDF膜均匀滴加发光液放入蛋白凝胶成像仪中进行发光拍摄图片,具体地蛋白凝胶成像图如图8所示,数据表明F蛋白和G蛋白的条带位置与实际的一致,证明了F蛋白和G蛋白成功表达。其中Control为重悬纯化病毒的1x病毒保护液。
实施例6呼吸道合胞病毒假病毒表达量
(1)A549和Hep-2细胞系使用含10%血清的DMEM培养基进行培养,复苏细胞超过三代后观察细胞生长状态,待细胞生长至80%-90%密度且细胞状态良好时进行铺孔96孔板,每种病毒3个复孔共计9个孔,铺孔密度30%-40%。
(2)第二天将10ul的呼吸道合胞病毒假病毒和1x助感染试剂混匀后加入96孔板中,孔板摇匀后置于含5% CO2的37℃细胞培养箱进行培养。
(3)感染72h小时后使用1xPBS(购自Gibco公司,货号为10-010-023)清洗细胞,胰酶消化后收集细胞进行1000rpm离心5min处理,离心完成后弃上清废液,细胞沉淀每个样品用双荧光素酶检测试剂盒(购自Promega公司,货号为E1910)中的50ul裂解液进行裂解后转移至酶标板,放入酶标仪中设置好程序进行检测,根据检测数据绘制柱状图进行分析,柱状图如图9所示,数据表明相对于对照来说病毒拥有较高的荧光强度。其中Control为未作处理的野生型细胞A549 WT/Hep-2 WT。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种呼吸道合胞病毒融合前F蛋白,其特征在于,所述的呼吸道合胞病毒融合前F蛋白与氨基酸序列如SEQ ID NO:6相比,含有以下突变中至少两种:N67I、N116Q、S215P、D486N。
2.根据权利要求1所述的呼吸道合胞病毒融合前F蛋白,其特征在于,所述的呼吸道合胞病毒融合前F蛋白的氨基酸序列如SEQ ID NO:1所示。
3.一种核酸分子,其特征在于,所述的核酸分子编码权利要求1-2任一项所述的呼吸道合胞病毒融合前F蛋白。
4.一种载体,其特征在于,所述的载体包含权利要求3所述的核酸分子。
5.一种呼吸道合胞病毒假病毒,其特征在于,包含权利要求1-2任一项所述的呼吸道合胞病毒融合前F蛋白。
6.权利要求5所述的呼吸道合胞病毒假病毒的制备方法,其特征在于,包括以下步骤:
(1)质粒pcDNA3.1+作为载体,利用限制性内切酶BamHI和EcoRI酶切获得线性化载体,通过同源重组将线性化的pcDNA3.1+载体分别与SEQ ID NO.1、SEQ ID NO:2、SEQ ID NO:3连接,分别获得pcDNA3.1-pre F质粒、pcDNA3.1-G质粒、pcDNA3.1-ZsGreen-IRES-Luc2质粒;
(2)在293T细胞中进行假病毒的包装,加入pcDNA3.1-pre F质粒、pcDNA3.1-G质粒、pcDNA3.1-ZsGreen-IRES-Luc2质粒和psPAX2质粒混匀,再加入1xPEI混匀,获得转染混合物;
(3)转染混合物加入到培养皿中,进行转染;
(4)离心,收集细胞培养基上清,加入病毒保护液进行重悬,再加入全能核酸酶,获得呼吸道合胞病毒假病毒。
7.权利要求1-2任一项所述的呼吸道合胞病毒融合前F蛋白或权利要求3所述的核酸分子或权利要求4所述的载体或权利要求5所述的呼吸道合胞病毒假病毒或权利要求6所述的制备方法制备得到的呼吸道合胞病毒假病毒在制备治疗、预防或辅助治疗呼吸道合胞病毒感染的药物中的应用。
8.权利要求1-2任一项所述的呼吸道合胞病毒融合前F蛋白或权利要求3所述的核酸分子或权利要求4所述的载体或权利要求5所述的呼吸道合胞病毒假病毒或权利要求6所述的制备方法制备得到的呼吸道合胞病毒假病毒在制备预防呼吸道合胞病毒感染的疫苗中的应用。
9.一种药物组合物,其特征在于,所述的药物组合物包含权利要求1-2任一项所述的呼吸道合胞病毒融合前F蛋白或权利要求3所述的核酸分子或权利要求4所述的载体或权利要求5所述的呼吸道合胞病毒假病毒或权利要求6所述的制备方法制备得到的呼吸道合胞病毒假病毒。
10.一种疫苗,其特征在于,所述的疫苗包含权利要求1-2任一项所述的呼吸道合胞病毒融合前F蛋白或权利要求3所述的核酸分子或权利要求4所述的载体或权利要求5所述的呼吸道合胞病毒假病毒或权利要求6所述的制备方法制备得到的呼吸道合胞病毒假病毒。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311839808.4A CN117886950A (zh) | 2023-12-28 | 2023-12-28 | 呼吸道合胞病毒假病毒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311839808.4A CN117886950A (zh) | 2023-12-28 | 2023-12-28 | 呼吸道合胞病毒假病毒及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117886950A true CN117886950A (zh) | 2024-04-16 |
Family
ID=90643863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311839808.4A Pending CN117886950A (zh) | 2023-12-28 | 2023-12-28 | 呼吸道合胞病毒假病毒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117886950A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002044334A2 (en) * | 2000-11-28 | 2002-06-06 | Aviron, Inc. | Recombinant rsv virus expression systems and vaccines |
US20140271699A1 (en) * | 2013-03-13 | 2014-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Prefusion rsv f proteins and their use |
WO2017207477A1 (en) * | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
CN112226450A (zh) * | 2020-08-25 | 2021-01-15 | 北京交通大学 | 一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗 |
CN112969786A (zh) * | 2018-10-12 | 2021-06-15 | Sk生物科学株式会社 | 重组呼吸道合胞病毒活疫苗株及其制备方法 |
CN116836243A (zh) * | 2022-09-23 | 2023-10-03 | 暨南大学 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
-
2023
- 2023-12-28 CN CN202311839808.4A patent/CN117886950A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002044334A2 (en) * | 2000-11-28 | 2002-06-06 | Aviron, Inc. | Recombinant rsv virus expression systems and vaccines |
US20140271699A1 (en) * | 2013-03-13 | 2014-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Prefusion rsv f proteins and their use |
WO2017207477A1 (en) * | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
CN112969786A (zh) * | 2018-10-12 | 2021-06-15 | Sk生物科学株式会社 | 重组呼吸道合胞病毒活疫苗株及其制备方法 |
CN112226450A (zh) * | 2020-08-25 | 2021-01-15 | 北京交通大学 | 一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗 |
CN116836243A (zh) * | 2022-09-23 | 2023-10-03 | 暨南大学 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
Non-Patent Citations (4)
Title |
---|
ANDERS KRARUP等: "A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism", NATURE COMMUNICATIONS, vol. 6, 3 September 2015 (2015-09-03), pages 1 - 12 * |
ANNELIES LEEMANS等: "Characterization of the role of N-glycosylation sites in the respiratory syncytial virus fusion protein in virus replication, syncytium formation and antigenicity", VIRUS RESEARCH, vol. 226, 31 July 2019 (2019-07-31), pages 58 - 68 * |
SUNEE TECHAARPORNKUL等: "Functional Analysis of Recombinant Respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene", JOURNAL OF VIROLOGY, vol. 75, no. 15, 30 August 2001 (2001-08-30), pages 6825 - 6834 * |
向江艳等: "呼吸道合胞病毒实时荧光定量PCR检测平台建立及分子流行病学特征", 中国优秀硕士学位论文 医药卫生科技, vol. 2, no. 1, 15 September 2020 (2020-09-15), pages 1 - 590 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111560354B (zh) | 重组新型冠状病毒及其制备方法和应用 | |
Liu et al. | Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy | |
CN113512096B (zh) | 一种鲈鱼弹状病毒重组g2蛋白及其应用 | |
CA3182052A1 (en) | Oral scars-cov-2 vaccine, preparation therefor, and application thereof | |
CN111676248A (zh) | 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建 | |
CN111744000B (zh) | 免疫抑制功能降低的口蹄疫重组病毒及其制备方法与应用 | |
CN105695491B (zh) | 鸡新城疫糖蛋白病毒抗原的制备方法及其产品 | |
WO2021208913A1 (zh) | 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用 | |
CN118146319B (zh) | 一种vzv重组蛋白及其制备方法和应用 | |
CN113896773B (zh) | 重组fcv抗原及猫嵌杯病毒基因工程亚单位疫苗 | |
CN113817753B (zh) | 表达SARS-CoV-2纤突蛋白或其变异体SΔ21的假型化VSV病毒构建和应用 | |
WO2005080419A1 (fr) | Agent polypeptide d'inhibition du coronavirus sars et ses derives et utilisations | |
CN117886950A (zh) | 呼吸道合胞病毒假病毒及其制备方法 | |
US20080267992A1 (en) | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine | |
AU2020103723A4 (en) | A Porcine Intestinal Epithelial Cell Line and Its Application | |
KR101316102B1 (ko) | 로타바이러스 나노입자를 이용한 재조합 복합 항원의 제조방법 | |
WO2013127300A1 (zh) | 用于抑制hiv的多肽、其药物组合物及其用途 | |
CN110184298B (zh) | Hiv突变型表面糖蛋白及其纳米化抗原与制备方法 | |
WO2005016247A2 (en) | Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars | |
JP2002017370A (ja) | 遺伝子組換えワクシニアウイルスワクチン | |
CN110408602B (zh) | Pcv2-prrsv重组病毒及其制备方法、基因、应用和疫苗 | |
CN118064456B (zh) | 一种针对人合胞病毒的新型的RSV B mRNA疫苗 | |
JP2941859B2 (ja) | Ha蛋白の製造法 | |
CN107488216B (zh) | 一种流感病毒通用疫苗及其制备方法与应用 | |
CN117736276A (zh) | 肠道病毒71型vp1蛋白高保守位点突变致流产株感染性克隆及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |